This title appears in the Scientific Report :
2021
Please use the identifier:
http://hdl.handle.net/2128/28890 in citations.
Please use the identifier: http://dx.doi.org/10.3233/JPD-202278 in citations.
Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study
Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study
Background:Sleep disturbances and neuropsychiatric symptoms are some of the most common nonmotor symptoms in Parkinson’s disease (PD). The effect of subthalamic stimulation (STN-DBS) on these symptoms beyond a short-term follow-up is unclear.Objective:To examine 36-month effects of bilateral STN-DBS...
Saved in:
Personal Name(s): | Jost, Stefanie T. |
---|---|
Ray Chaudhuri, K. / Ashkan, Keyoumars / Loehrer, Philipp A. / Silverdale, Monty / Rizos, Alexandra / Evans, Julian / Petry-Schmelzer, Jan Niklas / Barbe, Michael T. / Sauerbier, Anna / Fink, Gereon R. / Visser-Vandewalle, Veerle / Antonini, Angelo / Martinez-Martin, Pablo / Timmermann, Lars / Dafsari, Haidar S. (Corresponding author) | |
Contributing Institute: |
Kognitive Neurowissenschaften; INM-3 |
Published in: | Journal of Parkinson's Disease, 11 (2021) 1, S. 323 - 335 |
Imprint: |
Amsterdam
IOS Press
2021
|
PubMed ID: |
33074192 |
DOI: |
10.3233/JPD-202278 |
Document Type: |
Journal Article |
Research Program: |
Multilevel Brain Organization and Variability |
Link: |
OpenAccess Restricted |
Publikationsportal JuSER |
Please use the identifier: http://dx.doi.org/10.3233/JPD-202278 in citations.
Background:Sleep disturbances and neuropsychiatric symptoms are some of the most common nonmotor symptoms in Parkinson’s disease (PD). The effect of subthalamic stimulation (STN-DBS) on these symptoms beyond a short-term follow-up is unclear.Objective:To examine 36-month effects of bilateral STN-DBS on quality of sleep, depression, anxiety, and quality of life (QoL) compared to standard-of-care medical therapy (MED) in PD.Methods:In this prospective, controlled, observational, propensity score matched, international multicenter study, we assessed sleep disturbances using the PDSleep Scale-1 (PDSS), QoL employing the PDQuestionnaire-8 (PDQ-8), motor disorder with the Scales for Outcomes in PD (SCOPA), anxiety and depression with the Hospital Anxiety and Depression Scale (HADS), and dopaminergic medication requirements (LEDD). Within-group longitudinal outcome changes were tested using Wilcoxon signed-rank and between-group longitudinal differences of change scores with Mann-Whitney U tests. Spearman correlations analyzed the relationships of outcome parameter changes at follow-up.Results:Propensity score matching applied on 159 patients (STN-DBS n = 75, MED n = 84) resulted in 40 patients in each treatment group. At 36-month follow-up, STN-DBS led to significantly better PDSS and PDQ-8 change scores, which were significantly correlated. We observed no significant effects for HADS and no significant correlations between change scores in PDSS, HADS, and LEDD.Conclusions:We report Class IIb evidence of beneficial effects of STN-DBS on quality of sleep at 36-month follow-up, which were associated with QoL improvement independent of depression and dopaminergic medication. Our study highlights the importance of sleep for assessments of DBS outcomes. |